drugset
drugset / Trial / NCT05589961

Safety and Efficacy of TRPP Therapy in Glioblastoma Multiforme

NCT05589961 ↗

Phase 0 Unknown 10 enrolled The Second Hospital of Hebei Medical University
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to evaluate the safety of an innovative integrated treatment regimen for recurrent glioblastoma , including patients with recurrent glioblastoma multiforme.

Timeline

Start
2022-10
Primary completion
2024-07
Completion
2024-07

Drugs

EvaluationDrugModalityDoseRoute
Background Pembrolizumab Monoclonal antibody 200 mg —
Background TMZ Unknown 0.2 g —
Background Temozolomide Small molecule 50 mg/m2 Oral

Indications

glioblastoma